Skip to main content

Table 2 Comorbidities in relation to re-stenosis at 90 days

From: Triple platelet inhibition in intracranial thrombectomy with additional acute cervical stent angioplasty due to tandem lesion: a retrospective single-center analysis

  

n

Restenosis

OR (95%-KI)

p-value*

no

yes

AF

no

147

140 (95.2%)

7 (4.8%)

  
 

yes

29

28 (96.6%)

1 (3.4%)

0.71 (0.08–6.08)

1.000

diabetes

no

145

138 (95.2%)

7 (4.8%)

  
 

yes

31

30 (96.8%)

1 (3.2%)

0.66 (0.08–5.58)

1.000

cholesterol

no

149

141 (94.6%)

8 (5.4%)

  
 

yes

27

27 (100%)

0 (0%)

 

0.610

hypertension

no

67

65 (97.0%)

2 (3.0%)

  
 

yes

109

103 (94.5%)

6 (5.5%)

1.89 (0.37–9.74)

0.712

smoker

no

138

134 (97.1%)

4 (2.9%)

  
 

yes

38

34 (89.5%)

4 (10.5%)

3.94 (0.92–16.92)

0.067

cardiac disease

no

132

125 (94.7%)

7 (5.3%)

  
 

yes

44

43 (97.7%)

1 (2.3%)

0.42 (0.05–3.51)

0.681

Amount of comorbiditis

0

21

21 (100%)

0 (0%)

  

(AF-cardiac disease)

1

49

47 (95.9%)

2 (4.1%)

  
 

2

56

52 (92.9%)

4 (7.1%)

  
 

3

32

30 (93.8%)

2 (6.2%)

  
 

4

13

13 (100%)

0 (0%)

  
 

5

3

3 (100%)

0 (0%)

  
 

6

2

2 (100%)

0 (0%)

  

90 day mRS

0

24

23 (95.8%)

1 (4.2%)

  
 

1

33

30 (90.9%)

3 (9.1%)

  
 

2

22

21 (95.5%)

1 (4.5%)

  
 

3

23

20 (87.0%)

3 (13.0%)

  
 

4

32

32 (100%)

0 (0%)

  
 

5

11

11 (100%)

0 (0%)

  
 

6

31

31 (100%)

0 (0%)

  
  1. * Exact Fisher-Test